164 related articles for article (PubMed ID: 35247837)
1. Generation of a gene corrected human isogenic iPSC line (CPGHi001-A-1) from a hearing loss patient with the TMC1 p.M418K mutation using CRISPR/Cas9.
Wang H; Luo Y; Li J; Guan J; Yang S; Wang Q
Stem Cell Res; 2022 Apr; 60():102736. PubMed ID: 35247837
[TBL] [Abstract][Full Text] [Related]
2. Generation of a human induced pluripotent stem cell line (CPGHi001-A) from a hearing loss patient with the TMC1 p.M418K mutation.
Wang H; Wu K; Guan J; Wang Q
Stem Cell Res; 2020 Dec; 49():101982. PubMed ID: 33217648
[TBL] [Abstract][Full Text] [Related]
3. Genetic correction of induced pluripotent stem cells from a DFNA36 patient results in morphologic and functional recovery of derived hair cell-like cells.
Luo Y; Wu K; Zhang X; Wang H; Wang Q
Stem Cell Res Ther; 2024 Jan; 15(1):4. PubMed ID: 38167128
[TBL] [Abstract][Full Text] [Related]
4. Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology.
Fulgencio-Covián A; Álvarez M; Pepers BA; López-Márquez A; Ugarte M; Pérez B; van Roon-Mom WMC; Desviat LR; Richard E
Stem Cell Res; 2020 Dec; 49():102055. PubMed ID: 33128956
[TBL] [Abstract][Full Text] [Related]
5. Generation of a gene-corrected isogenic iPSC line (AHQUi001-A-1) from a patient with familial hypertriglyceridemia (FHTG) carrying a heterozygous p.C310R (c.928 T > C) mutation in LPL gene using CRISPR/Cas9.
Sun X; Zhou X; Dong B; Wang C; Xiao X; Wang Y
Stem Cell Res; 2021 Apr; 52():102230. PubMed ID: 33592566
[TBL] [Abstract][Full Text] [Related]
6. A novel DFNA36 mutation in TMC1 orthologous to the Beethoven (Bth) mouse associated with autosomal dominant hearing loss in a Chinese family.
Zhao Y; Wang D; Zong L; Zhao F; Guan L; Zhang P; Shi W; Lan L; Wang H; Li Q; Han B; Yang L; Jin X; Wang J; Wang J; Wang Q
PLoS One; 2014; 9(5):e97064. PubMed ID: 24827932
[TBL] [Abstract][Full Text] [Related]
7. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
[TBL] [Abstract][Full Text] [Related]
8. Generation of gene corrected human isogenic iPSC lines (IDVi003-A_CR13, IDVi003-A_CR21, IDVi003-A_CR24) from an inherited retinal dystrophy patient-derived IPSC line ITM2B-5286-3 (IDVi003-A) carrying the ITM2B c.782A > C variant using CRISPR/Cas9.
Ben Yacoub T; Letellier C; Wohlschlegel J; Condroyer C; Slembrouck-Brec A; Goureau O; Zeitz C; Audo I
Stem Cell Res; 2023 Sep; 71():103166. PubMed ID: 37473460
[TBL] [Abstract][Full Text] [Related]
9. Generation of a gene corrected human isogenic iPSC line (CPGHi002-A-1) from a DDOD patient with heterozygous c.1516 C>T mutation in the ATP6V1B2 gene.
Gao X; Qiu SW; Wang WQ; Kang DY; Su N; Dai P; Yuan YY
Stem Cell Res; 2021 May; 53():102271. PubMed ID: 33714068
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
[TBL] [Abstract][Full Text] [Related]
11. Generation of two isogenic knockout PKD2 iPS cell lines, IRFMNi003-A-1 and IRFMNi003-A-2, using CRISPR/Cas9 technology.
Trionfini P; Ciampi O; Romano E; Benigni A; Tomasoni S
Stem Cell Res; 2020 Jan; 42():101667. PubMed ID: 31830647
[TBL] [Abstract][Full Text] [Related]
12. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
[TBL] [Abstract][Full Text] [Related]
13. Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides.
Dong Y; Peng T; Wu W; Tan D; Liu X; Xie D
J Int Med Res; 2019 Apr; 47(4):1717-1730. PubMed ID: 30819013
[TBL] [Abstract][Full Text] [Related]
14. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs.
Li D; Ou M; Zhang W; Luo Q; Cai W; Mo C; Liang W; Dai G; Yin L; Zhu P; Tang D; Dai Y
Front Biosci (Landmark Ed); 2023 Jun; 28(6):131. PubMed ID: 37395026
[TBL] [Abstract][Full Text] [Related]
16. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
[TBL] [Abstract][Full Text] [Related]
17. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
Lilianty J; Bateman JF; Lamandé SR
Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
[TBL] [Abstract][Full Text] [Related]
18. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
19. Generation of a TMEM43 knockout human induced pluripotent stem cell line (HDZi003-A-1) using CRISPR/Cas9.
Ratnavadivel S; Dammeier J; Gaertner A; de Toledo MAS; Zenke M; Gummert J; Bloch Rasmussen T; Klinke N; Jürgens K; Meyer H; Paululat A; Milting H
Stem Cell Res; 2024 Apr; 76():103354. PubMed ID: 38430734
[TBL] [Abstract][Full Text] [Related]
20. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
Gao X; Tao Y; Lamas V; Huang M; Yeh WH; Pan B; Hu YJ; Hu JH; Thompson DB; Shu Y; Li Y; Wang H; Yang S; Xu Q; Polley DB; Liberman MC; Kong WJ; Holt JR; Chen ZY; Liu DR
Nature; 2018 Jan; 553(7687):217-221. PubMed ID: 29258297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
